SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

London-based Quant Network is set to revolutionise blockchain technology with the development of their blockchain operating system Overledger. The experienced team are determined to fulfil the original vision of the internet by creating an open trusted network for people, machines, and data to operate securely and safely.  Overledger -the first interoperable blockchain operating system that facilitates internet-scale development of decentralised, multi-chain applications. Overledger has the ability to unlock and distribute value and applications across current and future blockchains. It is an agnostic platform that connects the world's networks to blockchains and ensures you're not limited to any single a vendor or technology. Overledger is the only platform that facilitates the development of internet-scales development of decentralised, multi-chain applications.

Quant

Quants sharp rally and unusually heavy trading are being tied by traders to its Oracle-related digital-assets work and reported bank/tokenized-deposit initiatives, including The Clearing House. Bullish posts see institutional adoption and limited supply as supportive, while others question whether these partnerships create meaningful demand for QNT itself and point to the coins volatile pullback.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

New 24-month HOPE-3 extension data showing slower upper-limb decline after placebo patients switched to deramiocel has fueled optimism about Capricors Duchenne muscular dystrophy application. Traders are debating whether the findings can overcome the FDAs prior statistical objections ahead of its November review, with some also speculating about a short squeeze; approval remains uncertain.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Microns upcoming quarterly earnings report is the dominant focus, with traders watching whether tight DRAM and NAND supply, AI-related memory demand, and pricing momentum will support strong guidance. Bullish expectations are high, but the community is split over whether even a strong report could trigger a sell-the-news reaction and renewed doubts about how long the memory cycle can last.

Fair Isaac Corp. engages in the provision of decision management solutions. It operates through the Software and Scores segments. The Software segment includes pre-configured analytic and decision management solutions designed for a specific type of business need or process. The Scores segment focuses on business-to-business scoring solutions and services, business-to-consumer scoring solutions and services including myFICO solutions for consumers and associated professional services. The company was founded by Bill Fair and Earl Isaac in 1956 and is headquartered in San Jose, CA.

Fair Isaac Corp.

Fair, Isaac Corp.

FICO shares are under pressure as traders weigh FHFA changes allowing VantageScore alongside FICO in mortgage pricing, raising concerns that competition could erode FICOs mortgage-scoring dominance and pricing power. The debate centers on whether the selloff reflects a lasting threat to its moat or an overreaction, with bearish repricing concerns alongside dip-buying and expectations of a rebound.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

Attention centers on MoonLakes planned BLA filing for sonelokimab in hidradenitis suppurativa, with traders watching for filing confirmation and related clinical updates. The anticipated milestone is set against a sharp selloff that many attribute to the recent share offering and IZAR-1 results that tempered expectations for best-in-class efficacy, alongside criticism of management and its commercialization plans.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantirs sharp rebound and momentum toward the $200 level are drawing attention, with bulls tying the move to AI demand, commercial growth and confidence ahead of earnings. Bears counter that the valuation is stretched and point to Michael Burrys bearish stance, while bullish traders argue the companys execution and price strength outweigh those concerns.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings shares fell amid reports that prediction-market rival Kalshi is pursuing new financing, renewing concerns that Kalshi and Polymarket could take wagering share from traditional sportsbooks. Traders disagree on the impact: bears see a growing competitive threat, while bulls point to DraftKings own prediction-market growth and potential regulatory limits on rivals.

United States Natural Gas Fund LP. - United States Natural Gas Fund

United States Natural Gas Fund, LP

UNG is drawing attention amid volatile natural-gas trading, as traders weigh easing force-majeure disruption concerns and mild-weather demand against strong LNG export demand and tight global markets. The debate remains split: bears point to domestic supply and storage weighing on prices, while bulls see potential support from winter demand and global LNG needs.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances higher 2026 revenue outlook, reflecting stronger demand for Amtagvi and Proleukin, is the main catalyst behind the sharp share-price jump. Traders largely view the update as validation of the commercial ramp, while short-squeeze speculation and anticipation of lung-cancer data add to the enthusiasm; others caution that the stock may be overbought or face dilution risk.

Cheniere Energy, Inc. engages in liquefied natural gas (LNG) related businesses. It owns and operates LNG terminals, develops, constructs, and operates liquefaction projects near Corpus Christi, Texas, and at the Sabine Pass LNG terminal. The company was founded by Charif Souki in 1983 and is headquartered in Houston, TX.

Cheniere Energy Inc.

Discussion centers on Cheniere being passed over for S&P 500 inclusion after traders speculated it might be selected, with many attributing the sharp selloff to the snub or position unwinding. Some view the pullback as an overreaction, pointing to the Corpus Christi Stage 3 completion and raised guidance, while others remain focused on weak price action.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Did IOVA, ABCL, CRWD Stocks Surge To 52-Week Highs Today?

AbCellera is drawing attention after JPMorgan initiated coverage with an Overweight rating, citing promising ABCL635 results, while traders focus on the drugs Phase 2 data and a planned detailed presentation. The community is broadly bullish on the menopause-treatment candidate and the companys pipeline, though some caution that efficacy and safety still need validation in larger trials and debate whether the stocks sharp run-up may pull back.

The advance appears tied to JPMorgan initiating coverage with an Overweight rating and a $17 price target, citing promising ABCL635 clinical data and its efficacy, safety, and dosing convenience.

Why Did IOVA, ABCL, CRWD Stocks Surge To 52-Week Highs Today? 

Equity

The rallies were driven by expanding opportunities tied to biotechnology and artificial intelligence. 


Biotech And Biomimicry Stocks Lighting Up the Market

Biotech and life-science stocks are commanding attention as a fresh wave of momentum sweeps through the sector, with Silexion Therapeutics (NASDAQ:SLXN), Kraig Biocraft Laboratories (OTCQB:KBLB), 10x Genomics (NASDAQ:TXG), Moderna (NASDAQ:MRNA), AbCellera Biologics (NASDAQ:ABCL), Viatris (NASDAQ:VTRS), and Twist Bioscience (NASDAQ:TWST) among today’s notable names.

ABCL Stock Surges 121% in 3 Months: Here's What You Need to Know

AbCellera shares skyrocket 121% as positive ABCL635 data, major partnerships and a stronger financial position boost investor confidence.

AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026

AbCellera (Nasdaq: ABCL) today announced an upcoming oral presentation of Phase 2 data on ABCL635 at the International Menopause Society (IMS) 20th World Congress on Menopause, to be held September 30 to October 3, 2026 at the Windsor Ocenico Hotel and Congress Center in Rio de Janeiro, Brazil...

AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026

AbCellera (Nasdaq: ABCL) announced that the Company will present at the Cantor Global Healthcare Conference on September 9, 2026. A live audio webcast of the presentation may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through...

What'sGoing On With AbCellera Biologics Stock On Tuesday?

AbCellera Biologics stock gains as investors react to Jazz Pharmaceuticals' FDA approval and the companies' antibody partnership.read more...

Monday 8/17 Insider Buying Report: ABCL, BPRN

As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys.

At AbCellera Biologics, a filing with the SEC revealed that on Wednesday, Director...

AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants

AbCellera Biologics Inc. (Nasdaq: ABCL) (AbCellera) today announced the pricing of its oversubscribed underwritten public offering of 17,435,897 common shares at a price to the public of $9.75 per share and, in lieu of common shares to certain investors, pre-funded warrants to purchase up to...

What's Going on With AbCellera Biologics Stock On Wednesday?

AbCellera shares rise after positive ABCL635 Phase 2 results, while bullish momentum and analyst price targets point to further upside.read more...

National CineMedia Posts Downbeat Q2 Results, Joins Borr Drilling, AbCellera Biologics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

U.S. stock futures higher, Nasdaq 100 up 150 pts. National CineMedia shares down 16.4% on weak Q2 results and Captivate Holdings acquisition. Other stocks also falling in pre-market trading.read more...

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

Extremely Bullish Sentiment

Adding risk (buying more)

Trimming/taking profits

Rotating into safer assets

Staying the course, no changes

We&#39;re about to enter Q4 - how are you positioning your portfolio for the rest of the year?

Stocktwits

We're about to enter Q4 - how are you positioning your portfolio for the rest of the year?

Feed

News

Sentiment

Earnings

Fundamentals

Info

ABCL AbCellera Biologics Inc

Fundamentals

Latest ABCL News